161Tb-PSMA-I&T and177Lu-PSMA-I&T treatment in T23 and ST4787 prostate cancer cell lines - a model representative of177Lu-PSMA-resistant prostate cancer phenotype

被引：0
|
作者：
Kirienko, M. [1 ]
Jachetti, E. [1 ]
Sulsenti, R. [1 ]
Pascali, C. [1 ]
Bogni, A. [1 ]
Colombo, M. [1 ]
Seregni, E. [1 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2023年 / 50卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-0010
引用
收藏
页码：S434 / S435
页数：2
相关论文
共 50 条
  • [1] Lu-177-PSMA-I&T treatment in metastatic castration resistant prostate cancer: first experience in Thailand
    Khiewvan, Benjapa
    Danchaivijitr, Pongwut
    Rhoongsittichai, Kijja
    Shiratori, Shuichi
    Taweewatthanasopon, Nilmanee
    Thongpraparn, Thonnapong
    Poon-Iad, Nucharee
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [2] PSMA Radioligand Therapy of Metastasized Prostate Cancer Using Lu-177 PSMA I&T and Lu-177 PSMA-617: First comparative Dosimetric Results
    Schuchardt, C.
    Kulkarni, H. R.
    Wiessalla, S.
    Shahinfar, M.
    Singh, A.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S36 - S37
  • [3] 177Lu-PSMA-I&T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer:FirstClinical trialin Asia
    Bu, Ting
    Zhang, Pengjun
    Zang, Shiming
    Zhang, Lulu
    Wang, Feng
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [4] Optimising the Synthesis and QC of [177Lu]Lu-PSMA I&T for Prostate Cancer Therapy
    Hong, K.
    Fincher, L.
    Browne, E.
    INTERNAL MEDICINE JOURNAL, 2022, 52 : 53 - 54
  • [5] Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Philipp E. Hartrampf
    Franz-Xaver Weinzierl
    Andreas K. Buck
    Steven P. Rowe
    Takahiro Higuchi
    Anna Katharina Seitz
    Hubert Kübler
    Andreas Schirbel
    Markus Essler
    Ralph A. Bundschuh
    Rudolf A. Werner
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 3269 - 3276
  • [6] Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Hartrampf, Philipp E.
    Weinzierl, Franz-Xaver
    Buck, Andreas K.
    Rowe, Steven P.
    Higuchi, Takahiro
    Seitz, Anna Katharina
    Kuebler, Hubert
    Schirbel, Andreas
    Essler, Markus
    Bundschuh, Ralph A.
    Werner, Rudolf A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (09) : 3269 - 3276
  • [7] Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
    Abdlkadir, Ahmed Saad
    Abufara, Alaa
    Al-Ibraheem, Akram
    NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 58 (06) : 381 - 382
  • [8] Patient dosimetry of 177Lu-PSMA I&T in metastatic prostate cancer treatment: the experience in Thailand
    Kotchakorn Chatachot
    Shuichi Shiratori
    Tawatchai Chaiwatanarat
    Kitiwat Khamwan
    Annals of Nuclear Medicine, 2021, 35 : 1193 - 1202
  • [9] Patient dosimetry of 177Lu-PSMA I&T in metastatic prostate cancer treatment: the experience in Thailand
    Chatachot, Kotchakorn
    Shiratori, Shuichi
    Chaiwatanarat, Tawatchai
    Khamwan, Kitiwat
    ANNALS OF NUCLEAR MEDICINE, 2021, 35 (11) : 1193 - 1202
  • [10] 177Lu -PSMA-I&T PSMA radioligand therapy in metastatic castration - resistant prostate cancer: First clinical trial in Asia
    Bu, Ting
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2019, 62 : S527 - S528
12345